Eli Lilly and Company $LLY Stock Acquired by Generate Investment Management Ltd

Key Points

• Generate Investment Management increased its Eli Lilly stake by 8.4% in the third quarter, bringing its holdings to 57,065 shares valued at approximately $66 million. Institutional investors collectively own 82.53% of the company.
• Wall Street remains broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $1,313.43; analysts cited in the article set targets as high as $1,500.
• Eli Lilly’s stock rose 3.8% to $1,210.75, while its latest quarterly results exceeded expectations, with EPS of $8.38 versus $6.40 expected and revenue up 47.7% year over year.

Generate Investment Management Ltd raised its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 8.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 57,065 shares of the company's stock after acquiring an additional 4,409 shares during the quarter. Eli Lilly and Company makes up 2.6% of Generate Investment Management Ltd's portfolio, making the stock its 11th largest holding. Generate Investment Management Ltd's holdings in Eli Lilly and Company were worth $66,029,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. WestHill Financial Advisors Inc. acquired a new position in shares of Eli Lilly and Company during the third quarter valued at $485,000. MinichMacGregor Wealth Management LLC increased its stake in Eli Lilly and Company by 19.8% in the third quarter. MinichMacGregor Wealth Management LLC now owns 968 shares of the company's stock valued at $1,120,000 after purchasing an additional 160 shares in the last quarter. First Citizens Bank & Trust Co. raised its stake in Eli Lilly and Company by 22.3% during the 3rd quarter. First Citizens Bank & Trust Co. now owns 38,512 shares of the company's stock worth $44,561,000 after buying an additional 7,019 shares during the period. Focus Financial Network Inc. raised its position in shares of Eli Lilly and Company by 9.0% during the third quarter. Focus Financial Network Inc. now owns 7,646 shares of the company's stock worth $8,847,000 after purchasing an additional 632 shares during the period. Finally, Citrine Capital LLC boosted its holdings in shares of Eli Lilly and Company by 8.6% in the third quarter. Citrine Capital LLC now owns 239 shares of the company's stock valued at $277,000 after buying an additional 19 shares during the period. Institutional investors own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Bank of America boosted their price objective on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a "buy" rating in a research report on Friday, July 10th. BMO Capital Markets reiterated an "outperform" rating on shares of Eli Lilly and Company in a report on Thursday, October 1st. TD Cowen reissued a "buy" rating and issued a $1,250.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. Royal Bank Of Canada restated an "outperform" rating and issued a $1,500.00 price target on shares of Eli Lilly and Company in a report on Monday. Finally, Weiss Ratings upgraded Eli Lilly and Company from a "buy (b-)" rating to a "buy (b)" rating in a report on Wednesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,313.43.

Eli Lilly and Company Stock Up 3.8%

LLY traded up $44.24 during trading hours on Wednesday, hitting $1,210.75. 1,364,541 shares of the company's stock were exchanged, compared to its average volume of 2,943,851. The stock has a market cap of $1.14 trillion, a price-to-earnings ratio of 40.65, a PEG ratio of 1.52 and a beta of 0.46. Eli Lilly and Company has a 1-year low of $783.85 and a 1-year high of $1,292.65. The stock's 50-day moving average is $1,176.60 and its two-hundred day moving average is $1,102.08. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to analysts' expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. Eli Lilly and Company's revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter last year, the company earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts predict that Eli Lilly and Company will post 34.79 earnings per share for the current fiscal year.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong obesity and diabetes momentum: RBC expects Lilly could raise its full-year revenue outlook, supported by continued sales of Zepbound and other cardiometabolic products. Retatrutide is also viewed as a potentially larger future growth driver, with investor attention likely to intensify ahead of the company’s October 29 earnings report. RBC expects Lilly to raise revenue outlook
• Positive Sentiment: Favorable earnings expectations: Erste Group raised its FY2026 EPS estimate to $36.55 from $36.45 and its FY2027 estimate to $47.30. Analysts are also anticipating continued earnings growth in the upcoming third-quarter report. Eli Lilly earnings preview
• Positive Sentiment: Pipeline expansion: Lilly’s collaboration with Prelude Therapeutics will test an experimental breast-cancer drug in combination with established therapies, adding to its oncology pipeline. Broader industry cancer-drug spending is projected to exceed $400 billion by 2028, supporting long-term opportunity. Prelude clinical trial collaboration
• Neutral Sentiment: Valuation remains a key debate: Commentary highlights Lilly’s exceptional growth and potential undervaluation relative to its outlook, but the stock trades at a premium multiple, making execution and pipeline results important.
• Negative Sentiment: Clinical risks remain: A study of a combination involving Zepbound produced greater weight loss but substantially higher discontinuation rates, raising questions about tolerability and commercial adoption. Zepbound combination study

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald Zakrowski sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 13,500 shares of company stock valued at $15,958,170. Insiders own 0.14% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.